FDA Inspection 968356 — The Center for Reproductive Endocrinology
The FDA completed an inspection of The Center for Reproductive Endocrinology on April 13, 2016 in Dallas, TX. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 13, 2016
- Fiscal Year
- 2016
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Dallas, TX (United States)